

Market Announcement

24 September 2026

Healius Limited (ASX: HLS) – Trading Halt

Trading in the securities of Healius Limited ('HLS') will be halted at the request of HLS, pending the release of an announcement by HLS.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Monday, 28 September 2026; or
- the release of the announcement to the market.

HLS's request for a trading halt is attached below for the information of the market.

Issued by

ASX Compliance

Ms Renee Hutchens
Senior Adviser, Listings Supervision
ASX Limited
39 Martin Place
Sydney NSW 2000

By email: tradinghaltssydney@asx.com.au

24 September 2026

Dear Ms Hutchens,

Re: Request for Trading Halt: Healius Limited (ASX:HLS)

Healius Limited (**Healius**) requests that a trading halt be granted in respect of its securities with effect from commencement of trading today, Thursday, 24 September 2026, pursuant to ASX Listing Rule 17.1.

For the purposes of ASX Listing Rule 17.1, Healius advises that:

- (a) the trading halt is requested pending a material announcement regarding the Agilix Biolabs' sale process (**Announcement**);
- (b) it requests that the trading halt remain in place until the earlier of such time as it makes the Announcement, or the commencement of trading on Monday, 28 September 2026; and
- (c) it is not aware of any reason why the trading halt should not be granted, or of any information necessary to inform the market or ASX about the trading halt.

Yours sincerely,

A handwritten signature in black ink, appearing to be 'Paul Anderson', written in a cursive style.

Paul Anderson
Managing Director & CEO